We are also interested to work in B2B collaborations with other biotech companies specialized in cancer diagnostics. In particular we are interested in risk sharing collaborations focused on (i) early detection of cancer; (ii) identification and validation of prognostic cancer markers suitable for the prediction of patient outcome; (iii) identification and validation of drug response signatures. We also consider collaborations with companies specializing in the collection of high quality tumor samples.